Europe High Content Screening Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2024 –2030 |
 Marktgröße (Basisjahr) | |
 Marktgröße (Prognosejahr) | USD 1,057,169.94 |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Europäischer Markt für High-Content-Screening, nach Produkttyp (Instrumente, Verbrauchsmaterialien, Software, Dienstleistungen und Zubehör), Anwendung (Primär- und Sekundärscreening, Zielidentifizierung und -validierung, Toxizitätsstudien, Verbindungsprofilierung und andere Anwendungen), Technologie (Mikroskopie, Durchflusszytometrie , Immunhistochemie, auf der extrazellulären Matrix basierendes Gerüst, ELISA, Western Blotting und andere), Endbenutzer (Pharma- und Biotechnologieunternehmen, Auftragsforschungsinstitute, Labore, akademische und staatliche Institute, andere), Vertriebskanal (Direktausschreibungen, Einzelhandelsverkäufe) – Branchentrends und Prognose bis 2030.
Europa: High-Content-Screening – Marktanalyse und Einblicke
Die zunehmende Nutzung von HCS in Forschungsaktivitäten wie zellbasierter Analyse und Arzneimittelentdeckung hat die Nachfrage auf dem Markt erhöht. Die zunehmenden staatlichen Initiativen und die Finanzierung der Arzneimittelentdeckung und verwandter Forschungsprogramme tragen ebenfalls zum Marktwachstum bei. Die wichtigsten Marktteilnehmer konzentrieren sich in dieser entscheidenden Phase auf die Einführung und Zulassung verschiedener Dienste. Darüber hinaus trägt auch die zunehmende Weiterentwicklung von Bildgebungstechniken und künstlicher Intelligenz mit HCS-Systemen zur steigenden Nachfrage nach HCS bei.
Aufgrund der steigenden Zahl der Marktteilnehmer und der Verfügbarkeit hochtechnologischer HCS-Geräte wird für das Prognosejahr ein Marktwachstum erwartet. Darüber hinaus sind die Hersteller mit der Entwicklung von fortschrittlichen, neuartigen und effizienten HCS-Systemen beschäftigt. Die zunehmende Entwicklung im Bereich hochentwickelter Techniken dürfte das Marktwachstum weiter ankurbeln. Allerdings dürften Schwierigkeiten wie die strengen Vorschriften für die Herstellung und Vermarktung von HCS-Produkten das Marktwachstum bremsen.
Laut einer Analyse von Data Bridge Market Research wird der europäische Markt für High-Content-Screening voraussichtlich bis 2030 einen Wert von 1.057.169,94 Tausend US-Dollar erreichen, was einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 6,8 % während des Prognosezeitraums 2023–2030 entspricht.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2023 bis 2030 |
|
Basisjahr |
2022 |
|
Historische Jahre |
2021 (anpassbar auf 2015–2020) |
|
Quantitative Einheiten |
Umsatz in Tausend USD |
|
Abgedeckte Segmente |
Produkttyp (Instrumente, Verbrauchsmaterialien, Software, Dienstleistungen und Zubehör), Anwendung (Primär- und Sekundärscreening, Zielidentifizierung und -validierung, Toxizitätsstudien, Verbindungsprofilierung und andere Anwendungen), Technologie ( Mikroskopie , Durchflusszytometrie, Immunhistochemie, auf extrazellulärer Matrix basierendes Gerüst, ELISA, Western Blotting und andere), Endbenutzer (Pharma- und Biotechnologieunternehmen, Auftragsforschungsinstitute, Labore, akademische und staatliche Institute, andere), Vertriebskanal (Direktausschreibungen, Einzelhandelsverkäufe) |
|
Abgedeckte Länder |
Deutschland, Frankreich, Großbritannien, Italien, Spanien, Russland, Türkei, Belgien, Dänemark, Niederlande, Schweiz, Schweden, Polen, Norwegen, Finnland und Rest von Europa |
|
Abgedeckte Marktteilnehmer |
BD, Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, Zifo RnD Solutions, Axxam SpA, Molecular Devices, LLC. (Tochtergesellschaft der Danaher Corporation), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, Miltenyi Biotec, Aligned Genetics, Inc. und unter anderem |
Definition des europäischen High-Content-Screening-Marktes
High-Content Screening (HCS), auch bekannt als High-Content Analysis (HCA), ist ein Ansatz in der Zellbiologie, der automatisierte Bildgebung und quantitative Datenanalyse in einem Hochdurchsatzformat kombiniert, das für groß angelegte Anwendungen wie die Arzneimittelforschung und Systembiologie geeignet ist.
Dieser Markt bezieht sich auf den Sektor der Biowissenschaften, der sich auf den Einsatz moderner Bildgebungs- und Analysetechniken zur Untersuchung und Analyse zellulärer Prozesse und biologischer Phänomene im großen Maßstab konzentriert. HCS umfasst die automatisierte Bildgebung und quantitative Analyse von Zellen oder Organismen mithilfe von Technologien wie Fluoreszenzmikroskopie, automatisierter Flüssigkeitshandhabung und hochentwickelter Bildanalysesoftware.
Europa: Dynamik des High-Content-Screening-Marktes
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:
Treiber
- Fortschritte bei Bildgebungstechnologien für High Content Screening
Bildgebungstechnologien haben beim High-Content-Screening (HCS) eine Vorreiterrolle eingenommen und ermöglichen es Forschern, zelluläre Prozesse mit beispielloser Detailgenauigkeit und Präzision zu visualisieren und zu analysieren. Neben der hochauflösenden Bildgebung wurden auch Bildgebungsgeschwindigkeit und -durchsatz deutlich verbessert. HCS hilft bei der Analyse einer großen Anzahl von Proben, oft in Hochdurchsatzformaten. Bildgebungstechnologien wurden weiterentwickelt, um schnellere Erfassungszeiten zu ermöglichen, sodass Forscher große Datensätze in kürzerer Zeit analysieren können. Hochgeschwindigkeits-Bildgebungstechniken wie die konfokale Spinning-Disk-Mikroskopie und die Lichtblattmikroskopie ermöglichen eine schnelle Bildaufnahme ohne Kompromisse bei der Bildqualität und erleichtern so effiziente Screening-Workflows und Datenanalysen.
Im Laufe der Jahre wurden bedeutende Fortschritte bei Bildgebungsmodalitäten, Mikroskopietechniken und Bildanalysewerkzeugen erzielt, die die Landschaft des HCS veränderten und seine Marktexpansion vorantrieben.
Gelegenheit
- Zunehmende Integration von künstlicher Intelligenz und maschinellem Lernen in die Arzneimittelforschung und -entwicklung
KI-Techniken wie maschinelles Lernen und Deep Learning können große Datenmengen analysieren, die bei der Arzneimittelentdeckung und -entwicklung generiert werden. Durch die Verarbeitung unterschiedlicher Datensätze, darunter HTS-Daten, chemische und biologische Datenbanken sowie Daten aus klinischen Studien, können KI-Algorithmen Muster, Beziehungen und Trends erkennen, die für menschliche Forscher möglicherweise nicht sofort erkennbar sind. Dies kann dazu beitragen, die Identifizierung potenzieller Arzneimittelkandidaten zu beschleunigen und den Arzneimittelentdeckungsprozess zu optimieren.
Data Science und KI werden bei der Arzneimittelforschung und -entwicklung immer wichtiger. Neben der Entwicklung neuer Therapeutika beschleunigt KI auch die Arbeit bestehender Arzneimittelforschungs- und klinischer Teams und hilft ihnen, fundierte und hochpräzise Forschungsentscheidungen zu treffen.
Daher birgt die Einbindung künstlicher Intelligenz in die Arzneimittelforschung und -entwicklung das Potenzial, den Prozess zu beschleunigen, die Erfolgsquoten zu verbessern und die Kosten zu senken, was voraussichtlich Chancen für Marktwachstum schaffen wird.
Einschränkungen /Herausforderungen
- Komplexität zellulärer und molekularer Proben
Zelluläre und molekulare Proben sind von Natur aus komplex und bestehen aus mehreren zellulären Komponenten, komplizierten Signalwegen und dynamischen molekularen Interaktionen. Die Analyse einer solchen Komplexität erfordert fortschrittliche Bildgebungstechniken, spezielle Reagenzien und ausgefeilte Algorithmen, um die Daten genau zu erfassen und zu interpretieren. Die mit zellulären und molekularen Proben verbundene Komplexität stellt eine erhebliche Herausforderung dar, die das Marktwachstum voraussichtlich bremsen wird.
- Mangel an qualifizierten und zertifizierten Fachkräften für den Betrieb von HCS
Der Mangel an qualifizierten Fachkräften, die sich mit der Bedienung von HCS-Systemen auskennen, kann die Einführung und Nutzung dieser Technologien einschränken. Unternehmen zögern möglicherweise, in HCS-Plattformen zu investieren, wenn sie nicht über das notwendige Personal verfügen, um die Geräte effektiv zu bedienen und zu warten.
HCS erfordert Fachwissen im Umgang mit komplexen Bildgebungssystemen, Datenanalysesoftware und Assay-Optimierung. Unerfahrene Bediener haben möglicherweise Schwierigkeiten, Protokolle zu optimieren, was zu suboptimaler Leistung und beeinträchtigten Ergebnissen führt. Qualifizierte Fachkräfte sind entscheidend, um zuverlässige und qualitativ hochwertige Daten aus HCS-Assays zu erhalten. Daher wird erwartet, dass der Mangel an qualifizierten und zertifizierten Fachkräften für den Betrieb von HCS eine Herausforderung für das Marktwachstum darstellt.
Jüngste Entwicklungen
- Im Januar 2023 kündigte Axion BioSystems die Erweiterung der Omni Live-Cell-Imaging-Produktfamilie um den Omni Pro 12 an. Die neue Plattform mit integrierter Robotik und mehreren Designs, die mit jedem Standard-Inkubator kompatibel sind, bietet Wissenschaftlern und Arzneimittelentwicklern, die Live-Cell-Imaging-Experimente durchführen, mehr Flexibilität und Effizienz. Dieser Fortschritt in der Bildgebungstechnik würde dazu beitragen, die Arzneimittelforschung durch Live-Cell-Imaging-Experimente effizienter zu gestalten.
- Im Dezember 2019 kündigte Olympus die Markteinführung der scanR HCS-Station in den USA an, einer Zellbildgebungslösung, die künstliche Intelligenz (KI) nutzt, um biologische Forschung der nächsten Generation zu ermöglichen. Sie kombiniert die Modularität und Flexibilität eines mikroskopbasierten Aufbaus mit der Automatisierung, Geschwindigkeit, dem Durchsatz und der Reproduzierbarkeit einer HCS-Station. Die selbstlernende Mikroskopietechnologie von Olympus reduziert das Photobleichen und verbessert die Aufnahmegeschwindigkeit, Messempfindlichkeit und Genauigkeit, wodurch längere Beobachtungen mit geringerem Einfluss auf die Zelllebensfähigkeit ermöglicht werden.
Umfang des europäischen High-Content-Screening-Marktes
Der europäische Markt für High-Content-Screening ist in fünf wichtige Segmente unterteilt, basierend auf Produkttyp, Anwendung, Technologie, Endbenutzer und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Wachstumsnischen und Strategien zur Marktbearbeitung und bestimmt Ihre wichtigsten Anwendungsbereiche und die Unterschiede in Ihren Zielmärkten.
Produkttyp
- Instrumente
- Verbrauchsmaterial
- Software
- Dienstleistungen
- Zubehör
Auf der Grundlage des Produkttyps ist der Markt in Instrumente, Verbrauchsmaterialien, Software, Dienstleistungen und Zubehör segmentiert.
Anwendung
- Primäres und sekundäres Screening
- Zielidentifizierung und -validierung
- Toxizitätsstudien
- Compound-Profiling
- Sonstiges
Auf der Grundlage der Anwendung wird der Markt in Primär- und Sekundärscreening, Zielidentifizierung und -validierung, Toxizitätsstudien, Verbindungsprofilierung und Sonstiges segmentiert.
Technologie
- Mikroskopie
- Durchflusszytometrie
- Auf der extrazellulären Matrix basierendes Gerüst
- Western Blot
- ELISA
- Immunhistochemie
- Sonstiges
Auf der Grundlage der Technologie ist der Markt in Mikroskopie, Durchflusszytometrie, auf der extrazellulären Matrix basierendes Gerüst, Western Blotting, ELISA, Immunhistochemie und andere unterteilt.
Endbenutzer
- Pharma- und Biotechnologieunternehmen
- Akademische und staatliche Institute
- Auftragsforschungsinstitute
- Laboratorien
- Sonstiges
Auf der Grundlage des Endbenutzers wird der Markt in Pharma- und Biotechnologieunternehmen, akademische und staatliche Institute, Auftragsforschungsinstitute, Labore und andere segmentiert.
Vertriebskanal
- Direkte Ausschreibungen
- Einzelhandelsumsätze
Auf der Grundlage des Vertriebskanals wird der Markt in Direktausschreibungen und Einzelhandelsverkäufe segmentiert .
Europa High Content Screening Markt – Regionale Analyse/Einblicke
Der europäische Markt für High-Content-Screening ist basierend auf Produkttyp, Anwendung, Technologie, Endbenutzer und Vertriebskanal in fünf wichtige Segmente unterteilt.
Die in diesem Marktbericht abgedeckten Länder sind Deutschland, Frankreich, Großbritannien, Italien, Spanien, Russland, Türkei, Belgien, Dänemark, Niederlande, Schweiz, Schweden, Polen, Norwegen, Finnland und das übrige Europa.
Aufgrund der steigenden Investitionen in High-Content-Screening und der steigenden Nachfrage aus den Schwellenmärkten und der Expansion wird Deutschland voraussichtlich die Region Europa dominieren, was das Marktwachstum ankurbeln dürfte.
Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, demografische Daten des Landes, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit europäischer Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.
Wettbewerbsumfeld und Marktanteilsanalyse für High-Content-Screening in Europa
Die Wettbewerbslandschaft des europäischen Marktes für High-Content-Screening liefert Details nach Wettbewerbern. Die enthaltenen Details sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktzulassungen, Produktbreite und -breite, Anwendungsdominanz, Produkttyp-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens auf den europäischen Markt für High-Content-Screening.
Zu den wichtigsten Marktteilnehmern auf dem europäischen High-Content-Screening-Markt zählen unter anderem BD, Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, Zifo RnD Solutions, Axxam SpA, Molecular Devices, LLC. (Tochtergesellschaft der Danaher Corporation), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, Miltenyi Biotec, Aligned Genetics, Inc. und andere.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE HIGH CONTENT SCREENING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EUROPE HIGH CONTENT SCREENING MARKET: REGULATIONS
6 MARKET OVERVIEW, EUROPE HIGH CONTENT SCREENING MARKET
6.1 DRIVERS
6.1.1 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH CONTENT SCREENING
6.1.2 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.1.3 INCREASING RESEARCH ACTIVITIES ASSOCIATED WITH THE USAGE OF HIGH CONTENT SCREENING
6.1.4 INCREASING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH INITIAL SETUP AND MAINTENANCE
6.2.2 COMPLEXITY ASSOCIATED WITH CELLULAR AND MOLECULAR SAMPLES
6.3 OPPORTUNITIES
6.3.1 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS) PROVIDING HCS SERVICES
6.3.2 RISING INTEGRATION WITH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT
6.3.3 INCREASING GOVERNMENT INITIATIVE AND FUNDING IN R&D
6.4 CHALLENGES
6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE HCS
6.4.2 DATA SECURITY AND DATA MANAGEMENT PROBLEMS IN HCS
7 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 CELL IMAGING AND ANALYSIS SYSTEM
7.2.1.1 FIXED
7.2.1.2 MOBILE
7.2.2 HIGH-CONTENT AND SCREENING SYSTEM
7.2.2.1 FIXED
7.2.2.2 MOBILE
7.2.3 FLOW CYTOMETRY
7.2.4 INVITROGEN HCA ONSTAGE INCUBATOR
7.2.5 MICROPLATE MOVER
7.2.6 OTHERS
7.3 SOFTWARE
7.4 CONSUMABLES
7.4.1 REAGENTS & ASSAY KITS
7.4.2 MICROPLATES
7.4.3 OTHERS
7.5 ACCESSORIES
7.6 SERVICES
8 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 PRIMARY AND SECONDARY SCREENING
8.2.1 INSTRUMENTS
8.2.2 CONSUMABLES
8.2.3 ACCESSORIES
8.2.4 SERVICES
8.3 TARGET IDENTIFICATION AND VALIDATION
8.3.1 INSTRUMENTS
8.3.2 CONSUMABLES
8.3.3 ACCESSORIES
8.3.4 SERVICES
8.4 TOXICITY STUDIES
8.4.1 INSTRUMENTS
8.4.2 CONSUMABLES
8.4.3 ACCESSORIES
8.4.4 SERVICES
8.5 COMPOUND PROFILING
8.5.1 INSTRUMENTS
8.5.2 CONSUMABLES
8.5.3 ACCESSORIES
8.5.4 SERVICES
8.6 OTHER APPLICATIONS
9 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 MICROSCOPY
9.3 FLOW CYTOMETRY
9.4 IMMUNOHISTOCHEMISTRY
9.5 MASS SPECTROMETRY
9.6 ELISA
9.7 WESTERN BLOTTING
9.8 OTHERS
9.8.1 3D CELL CULTURE MODEL
9.8.1.1 STEROIDS
9.8.1.2 ORGANOIDS
9.8.1.3 TISSUE ON A CHIP
9.8.2 EXTRACELLULAR MATRIX BASED SCAFFOLD
9.8.3 SYNTHETIC HYDROGEL AND SCAFFOLD
10 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER
10.1 OVERVIEW
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 ACCESSORIES
10.2.4 SERVICES
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.3.1 INSTRUMENTS
10.3.2 CONSUMABLES
10.3.3 ACCESSORIES
10.3.4 SERVICES
10.4 LABORATORIES
10.4.1 INSTRUMENTS
10.4.2 CONSUMABLES
10.4.3 ACCESSORIES
10.4.4 SERVICES
10.5 ACADEMIC AND GOVERNMENT INSTITUTES
10.5.1 INSTRUMENTS
10.5.2 CONSUMABLES
10.5.3 ACCESSORIES
10.5.4 SERVICES
10.6 OTHERS
11 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDERS
11.3 RETAIL SALES
12 EUROPE HIGH CONTENT SCREENING MARKET, BY REGION
12.1 OVERVIEW
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 RUSSIA
12.1.7 TURKEY
12.1.8 BELGIUM
12.1.9 DENMARK
12.1.10 NETHERLANDS
12.1.11 SWITZERLAND
12.1.12 SWEDEN
12.1.13 POLAND
12.1.14 NORWAY
12.1.15 FINLAND
12.1.16 REST OF EUROPE
13 EUROPE HIGH CONTENT SCREENING MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 EUROPE CONTENT SCREENING MARKET, COMPANY PROFILES
14.1 THERMO FISHER SCIENTIFIC INC. (2022)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 MOLECULAR DEVICES, LLC. (A SUBSIDIARY OF DANAHER CORPORATION)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 PERKINELMER INC. (2022)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 YOKOGAWA ELECTRIC CORPORATION (2022)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 BD
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENTS
14.6 MERCK KGAA
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 AGILENT TECHNOLOGIES, INC. (2022)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ALIGNED GENETICS, INC. (2022)
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 AXXAM S.P.A.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 BIO-RAD LABORATORIES, INC. (2022)
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 CARL ZEISS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CORNING INCORPORATED
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GENEDATA AG
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MILTENYI BIOTEC
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 SARTORIUS AG
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 SYSMEX CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENT
14.17 ZIFO RND SOLUTIONS
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 EUROPE INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE HIGH-CONTENT AND SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 13 EUROPE 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 14 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 15 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 EUROPE LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 EUROPE ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 20 EUROPE HIGH CONTENT SCREENING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 21 GERMANY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 GERMANY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 GERMANY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 GERMANY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 GERMANY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 26 GERMANY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 27 GERMANY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 GERMANY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 29 GERMANY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 GERMANY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 31 GERMANY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 32 GERMANY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 33 GERMANY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 34 GERMANY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 35 GERMANY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 GERMANY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 37 GERMANY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 GERMANY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 GERMANY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 40 FRANCE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 FRANCE INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 FRANCE CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 FRANCE HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 FRANCE CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 FRANCE HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 46 FRANCE PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 47 FRANCE TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 FRANCE TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 FRANCE COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 FRANCE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 51 FRANCE OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 52 FRANCE 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 53 FRANCE HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 54 FRANCE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 FRANCE CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 FRANCE LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 FRANCE ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 FRANCE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 59 U.K. HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 U.K. INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 U.K. CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 U.K. HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 U.K. CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 U.K. HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 65 U.K. PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 U.K. TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 U.K. TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 U.K. COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 U.K. HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 70 U.K. OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 71 U.K. 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 72 U.K. HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 73 U.K. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 74 U.K. CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 U.K. LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 76 U.K. ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 U.K. HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 78 ITALY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 ITALY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 ITALY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 ITALY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 ITALY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 ITALY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 84 ITALY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 ITALY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 ITALY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 ITALY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 ITALY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 89 ITALY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 90 ITALY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 91 ITALY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 92 ITALY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 ITALY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 ITALY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 ITALY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 96 ITALY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 97 SPAIN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 SPAIN INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 SPAIN CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 SPAIN HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 SPAIN CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 SPAIN HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 103 SPAIN PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 104 SPAIN TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 105 SPAIN TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 SPAIN COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 SPAIN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 108 SPAIN OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 109 SPAIN 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 110 SPAIN HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 111 SPAIN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 SPAIN CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 SPAIN LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 SPAIN ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 SPAIN HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 116 RUSSIA HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 RUSSIA INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 RUSSIA CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 RUSSIA HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 RUSSIA CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 RUSSIA HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 122 RUSSIA PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 RUSSIA TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 RUSSIA TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 RUSSIA COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 RUSSIA HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 127 RUSSIA OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 128 RUSSIA 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 129 RUSSIA HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 130 RUSSIA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 RUSSIA CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 132 RUSSIA LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 RUSSIA ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 134 RUSSIA HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 135 TURKEY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 TURKEY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 137 TURKEY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 TURKEY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 TURKEY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 TURKEY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 141 TURKEY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 TURKEY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 143 TURKEY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 TURKEY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 TURKEY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 146 TURKEY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 147 TURKEY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 148 TURKEY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 149 TURKEY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 TURKEY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 TURKEY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 152 TURKEY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 153 TURKEY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 154 BELGIUM HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 BELGIUM INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 BELGIUM CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 BELGIUM HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 BELGIUM CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 BELGIUM HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 160 BELGIUM PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 BELGIUM TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 BELGIUM TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 BELGIUM COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 BELGIUM HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 165 BELGIUM OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 166 BELGIUM 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 167 BELGIUM HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 168 BELGIUM PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 169 BELGIUM CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 170 BELGIUM LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 BELGIUM ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 BELGIUM HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 173 DENMARK HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 DENMARK INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 DENMARK CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 DENMARK HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 DENMARK CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 DENMARK HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 179 DENMARK PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 DENMARK TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 DENMARK TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 DENMARK COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 DENMARK HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 184 DENMARK OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 185 DENMARK 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 186 DENMARK HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 187 DENMARK PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 DENMARK CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 DENMARK LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 DENMARK ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 191 DENMARK HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 192 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 NETHERLANDS INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 NETHERLANDS CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 195 NETHERLANDS HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 NETHERLANDS CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 198 NETHERLANDS PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 NETHERLANDS TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 200 NETHERLANDS TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 201 NETHERLANDS COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 202 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 203 NETHERLANDS OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 204 NETHERLANDS 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 205 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 206 NETHERLANDS PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 207 NETHERLANDS CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 NETHERLANDS LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 NETHERLANDS ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 211 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 SWITZERLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 SWITZERLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 SWITZERLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 SWITZERLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 217 SWITZERLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 SWITZERLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 219 SWITZERLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SWITZERLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 222 SWITZERLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 223 SWITZERLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 224 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 225 SWITZERLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 SWITZERLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 SWITZERLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 228 SWITZERLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 229 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 230 SWEDEN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 SWEDEN INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 232 SWEDEN CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 233 SWEDEN HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 SWEDEN CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 SWEDEN HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 236 SWEDEN PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 SWEDEN TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 238 SWEDEN TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 239 SWEDEN COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 240 SWEDEN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 241 SWEDEN OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 242 SWEDEN 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 243 SWEDEN HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 244 SWEDEN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 SWEDEN CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 SWEDEN LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 SWEDEN ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 248 SWEDEN HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 249 POLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 POLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 251 POLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 POLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 POLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 254 POLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 POLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 POLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 257 POLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 258 POLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 POLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 260 POLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 261 POLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 262 POLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 263 POLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 POLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 265 POLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 266 POLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 267 POLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 268 NORWAY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 269 NORWAY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 270 NORWAY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 271 NORWAY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 272 NORWAY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 273 NORWAY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 274 NORWAY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 NORWAY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 NORWAY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 NORWAY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 NORWAY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 279 NORWAY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 280 NORWAY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 281 NORWAY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 282 NORWAY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 NORWAY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 284 NORWAY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 285 NORWAY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 286 NORWAY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 287 FINLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 288 FINLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 FINLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 FINLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 FINLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 FINLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 293 FINLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 FINLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 295 FINLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 FINLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 297 FINLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 298 FINLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 299 FINLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 300 FINLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 301 FINLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 302 FINLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 303 FINLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 304 FINLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 305 FINLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 306 REST OF EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
Abbildungsverzeichnis
FIGURE 1 EUROPE HIGH CONTENT SCREENING MARKET: SEGMENTATION
FIGURE 2 EUROPE HIGH CONTENT SCREENING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HIGH CONTENT SCREENING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HIGH CONTENT SCREENING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HIGH CONTENT SCREENING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HIGH CONTENT SCREENING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HIGH CONTENT SCREENING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE HIGH CONTENT SCREENING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE HIGH CONTENT SCREENING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HIGH CONTENT SCREENING MARKET: SEGMENTATION
FIGURE 11 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH-CONTENT SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE HIGH CONTENT SCREENING MARKET IN THE FORECAST PERIOD
FIGURE 12 THE PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HIGH CONTENT SCREENING MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE HIGH CONTENT SCREENING MARKET
FIGURE 14 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, 2022
FIGURE 19 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 20 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 21 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, 2022
FIGURE 23 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, 2023-2030 (USD THOUSAND)
FIGURE 24 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 25 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, 2022
FIGURE 27 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 32 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE HIGH CONTENT SCREENING MARKET: SNAPSHOT (2022)
FIGURE 35 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2022)
FIGURE 36 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 39 EUROPE HIGH CONTENT SCREENING MARKET: COMPANY SHARE 2022 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
